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difference between MAC vs RIC for OS, LFS, RI and NRM
(Figure 1).
The analyses were performed separately for pts <50 and
50 year group. Among older cohorts (age 50), there was a
signiﬁcant advantage of RIC regimen with higher OS (44.6 vs
37.1%; p¼0.01), LFS (40.3 vs 34.3%; p¼0.03), decreased NRM
(29.6% vs 35.8%; p¼0.05), but no differences in RI (p¼0.95). A
higher cumulative incidence of cGVHD was seen after RIC
(37.6 vs 24.3%; p¼0.0009). Among younger cohort (age<50),
MAC showed no differences in OS, NRM and cGVHD
compared to the RIC group.
In multivariate analysis (age 50), higher OS (HR 0.78;
p¼0.01), LFS (HR 0.82; p¼0.05), and decreased NRM (HR
0.73; p¼0.03) were seen after RIC. RI (HR 0.91; p¼0.51) and
cGVHD (HR 1.31; p¼0.11) were, however, not signiﬁcantly
different. Pts<50 years old showed no differences in OS, LFS,
RI, NRM, and cGVHD between MAC or RIC group.
Conclusion: Our study shows no signiﬁcant outcome
difference between RIC and MAC regimens after MM URD
allo-SCT in pts younger than 50 years. Furthermore, data
support superiority of RIC regimen in older adults receiving
transplant from MM URD.IMMUNE RECONSTITUTION55
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Figure 1A. Longitudinal analysis of total CDB+ naive and effector memory (TEM) subsets depicted as % frequency of CDB+ T cells. Data are mean  SEM in + CMV
patients (n¼7) - CMV patients (n¼10) and healthy controls of (n¼10). Also shown is the mean day of CMV reactivation ( SEM), depicted as purple bar. Figure 1B:
Respresentative TCR deep sequencing landscapes of CDB+ Naive (left column)and CDB+ TEM (right column), showing frequencies of V and J gene combinations
detected through deep sequencing from one patient without CMV reactivation (blue) and one patient with CMV reactivation (red). This representative data illustrates
the increased TCR elenaity of the CDB Tem measured in the patients who reactivated CMV.
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Although CMV reactivation has long been implicated in
post-transplant immune dysfunction, the molecular mech-
anisms by which even a single reactivation event can in-
crease the risk of transplant-related mortality remains a
mystery. To address this, we combined multiparameter ﬂow
cytometric analysis and T cell subpopulation sorting with
high-throughput sequencing of the T cell repertoire, to pro-
duce an exhaustive evaluation of the impact of CMV reac-
tivation on T cell reconstitution after BMT. These studies
were performed in an initial cohort of 17 transplant patients,
with an ongoing validation cohort consisting of an additional
19 patients (n ¼ 36 total). We discovered that a single CMV
reactivation event was sufﬁcient to drive a >50-fold speciﬁc
expansion of Granzyme Bhigh/CD28low/CD57high/CD8+
effector-memory T cells (Figure 1A) and, surprisingly, to
result in a linked contraction of all naive T cells, including
CD31+/CD4+ putative thymic emigrants. TCRb deepsequencing revealed that CMV reactivation drove a striking
contraction of CD8+ Tem diversity compared to the diversity
observed in patients that did not reactivate CMV (Figure 1B).
Deep sequence analysis of clonally expanded CD8+ Tem and
of puriﬁed CMV-speciﬁc tetramer+ CD8+ T cells provided
molecular conﬁrmation that the CD8 Tem clonal expansion
was driven by expansion of CMV-speciﬁc clones.
In addition to querying the topography of the expanding
CMV-speciﬁc T cell clones, deep sequencing allowed us, for
the ﬁrst time, to exhaustively evaluate the rest of the TCR
repertoire (in non-CMV-speciﬁc T cells). Our results reveal
new evidence for signiﬁcant holes in the underlying TCR
repertoire in patients who reactivate CMV, suggesting that
CMV reactivation is associated with a linked expansion of
CMV-speciﬁc T cells and a contraction of other clones in the
context of post-transplant immune reconstitution.
These data provide compelling evidence that key aspects
of immunologic skewing during hematopoietic reconstitu-
tion are driven by CMV reactivation, and provide the ﬁrst
molecular evidence that in addition to driving expansion of
virus-speciﬁc cells, CMV reactivation has a detrimental
impact on the integrity and heterogeneity of the rest of the
T cell repertoire.
